310. Congenital anomalies syndrome Clinical trials / Disease details
Clinical trials : 11 / Drugs : 20 - (DrugBank : 10) / Drug target genes : 3 - Drug target pathways : 7
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03720990 (ClinicalTrials.gov) | March 27, 2021 | 24/10/2018 | Smith-Lemli-Opitz Syndrome and Cholic Acid | Smith-Lemli-Opitz Syndrome: A Pilot Study of Cholic Acid Supplementation | Smith-Lemli-Opitz Syndrome | Drug: Cholic Acid | University of Nebraska | University of Colorado, Denver;Children's Hospital Medical Center, Cincinnati;University of Pittsburgh | Active, not recruiting | 2 Years | 25 Years | All | 12 | Phase 1/Phase 2 | United States |